| 参 考 文 献 |
|
1)～23)は「わが国の臨床試験とそれを評価するための枠組み─1 文献」を参照 |
24) |
Ono S, Kodama Y, Nagao T, Toyoshima S. The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections. Controlled Clinical Trial (in press). |
| 25) |
児玉庸夫. GCP適合性実地調査の現状. 大阪医薬品協会会報 平成12年9月; 620: 25-45. |
| 26) |
Horowitz AM. Fraud and scientific misconduct in the United States. In: Lock S, Wells F, eds. Fraud and misconduct in medical research 2nd ed. London: BMJ Publishing Group; 1996. |
| 27) |
Huddleston RD. FDA clinical investigator site inspections: the sponsor's role. Drug Information Journal 1999; 33: 965-8. |
| 28) |
Fukuhara S, Tanabe N, Kurokawa K. Background issues in Japan affecting the ethical review process for clinical trials. Int J Pharmaceut Med 1999;13:25-8. |
| 29) |
上田慶二, 福原俊一, Glickman P, 田邊昇, 黒川清. 新GCP導入がわが国の臨床試験に与えた影響と問題に関する調査. 臨床評価 1999; 27: 371-38. |
| 30) |
Ikegami N, Mitchell W, Penner-Hahn J. Pharmaceutical prices, quantities and innovation. Comparing Japan with the US. Pharmacoeconomics 1994; 6: 424-33. |
| 31) |
Tominaga T. Japan's New GCP regulations and their impact on clinical trials. In: Tominaga T, ed. Japan's new GCP and other rules on clinical trials (Part 3). Tokyo: Yakuji Nippo; 1999. |
| 32) |
Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatment. Ann Intern Med 2000; 133: 455-63. |
| 33) |
International Conference on Harmonisation (ICH) Harmonised Tripartite Guideline. Choice of control group and related issues in clinical trials. Geneva: ICH-secretariat, 2000. |
| 34) |
Shapiro MF, Charrow RP. Scientific misconduct in investigational drug trials. N Engl J Med 1985; 312: 731-6. |
| 35) |
Weiss RB, Vogelzang NJ, Peterson BA, Panasci LC, Carpenter JT, Gavigan M, Sartell K, Frei E, Mclntyre OR. A successful system of scientific data audits for clinical trials: a report from the Cancer and Leukemia Group B. JAMA 1993; 270: 459-64. |
| 36) |
朝日新聞, 1997 Jan 22:30. |
| 37) |
Lepay DA. GCP compliance: FDA expectations and recent findings [on line]. Available from: URL: http://www.fda.gov/cder/present/dia698/diafda2/index.htm [Accessed on 2001 May 24]. |
| 38) |
Lisook AB. FDA audits of clinical studies: policy and procedure. J Clin Pharmacol 1990; 30: 296-302. |
| 39) |
小野俊介. GCP調査と承認審査の好ましいあり方について. 日本QA研究会会報 1998 May; 10: 77-88. |
| 40) |
小野俊介. 治験の「質」の定義に関する考察. 臨床薬理 1998; 29(3): 591-2. |
| 41) |
小野俊介. 治験現場からみたモニタリングおよび監査. 行政の立場から. 臨床医薬 1998; 14(14): 2510-2. |
| 42) |
中野重行. 日本の治験におけるインフォームド・コンセントの実態. 薬理と治療 1997; 25(9): 2223-47. |
| 43) |
Kolata G, Eigenwald K. For the uninsured, experiments may provide the only treatment. New York Times 1999 Jun 22 [on line] |
| 44) |
Helsinki's New Clinical Rules: Fewer Placebos, More Disclosure. Science 2000; 290: 418-9. |
| 45) |
永井 , 大西純一. GCP調査の現状と問題点. 臨床評価2002;29(2・3):315-32. |